Clinical Trial Update: Companion Pharmacogenetic Study to UMCC 9900/9901

View source ↗

Summary

A companion pharmacogenetic study to UMCC 9900/9901 in metastatic breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Metastatic Breast Cancer | Status: TERMINATED